Tripep receives approval for expanding the ChronVac-C® study with one more vaccination

Tripep receives approval for expanding the ChronVac-C® study with one more
vaccination

Today Tripep received the approval from the Swedish Medical Products Agency and 
the local ethical committee to give three patients in the highest dose group in
the ChronVac-C® study one additional treatment with the therapeutic vaccine. All
twelve patients in the study have earlier received four treatments with
ChronVac-C® given at three different doses and one month apart. The highest dose
was given to six patients. Three patients in the high dose group will now be
offered to receive a fifth therapeutic vaccination with ChronVac-C® 6 to 12
months after the last vaccination before receiving standard of therapy with
interferon and ribavirin. The purpose is to determine if there are beneficial
effects from additional so called booster-doses. The three patients will be
followed for one month after the fifth therapeutic vaccination where after they
also receive standard of therapy.


Tripep has earlier reported on the positive outcome with the activation of an
immune response against hepatitis C virus as well as a reduction of the levels
of virus in the blood in the phase I/II study where patients are treated with
the therapeutic vaccine ChronVac-C®. The study has now been extended with an
additional booster-dose for three patients in the highest dose group to test if
an extra dose given after a resting period has beneficial effects. Tripep has
also reported that the three patients who already after the vaccinations have
received standard of care seemed to respond with an unusually rapid elimination
of the virus from the blood. All patients, including the three who will receive
an extra vaccination will be followed closely when on standard of therapy to
find out if pretreatment with ChronVac-C® may give a better and faster treatment
result when on standard of care. 

”We are very happy that the ChronVac-C® treatment can be extended without
further preclinical studies which will speed up the clinical development. It is
with great excitement that we look forward to receiving the results from this
extra so called booster-injection  with ChronVac-C®. In parallel we follow with
excitement also the patients from the ChronVac-C® study who now receive standard
of therapy with interferon and ribavirin”, says Tripep's CEO and Head of
Research Anders Vahlne. 

For more information, please contact:

Anders Vahlne, CEO and Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, 
E-mail: anders.vahlne@ki.se

Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.